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Abstract: Progressive respiratory failure is seen as a major cause of death in severe acute respiratory
syndrome coronavirus 2 (SARS-Cov-2)-induced infection. Relatively little is known about the
associated morphologic and molecular changes in the circulation of these patients. In particular,
platelet and erythrocyte pathology might result in severe vascular issues, and the manifestations
may include thrombotic complications. These thrombotic pathologies may be both extrapulmonary
and intrapulmonary and may be central to respiratory failure. Previously, we reported the presence
of amyloid microclots in the circulation of patients with coronavirus disease 2019 (COVID-19).
Here, we investigate the presence of related circulating biomarkers, including C-reactive protein
(CRP), serum ferritin, and P-selectin. These biomarkers are well-known to interact with, and cause
pathology to, platelets and erythrocytes. We also study the structure of platelets and erythrocytes using
fluorescence microscopy (using the markers PAC-1 and CD62PE) and scanning electron microscopy.
Thromboelastography and viscometry were also used to study coagulation parameters and plasma
viscosity. We conclude that structural pathologies found in platelets and erythrocytes, together with
spontaneously formed amyloid microclots, may be central to vascular changes observed during
COVID-19 progression, including thrombotic microangiopathy, diffuse intravascular coagulation,
and large-vessel thrombosis, as well as ground-glass opacities in the lungs. Consequently, this clinical
snapshot of COVID-19 strongly suggests that it is also a true vascular disease and considering it as
such should form an essential part of a clinical treatment regime.
Keywords: COVID-19; erythrocytes; platelets; P-selectin; serum ferritin; oxygen saturation
1. Introduction
Severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2)-induced infection, leading to
coronavirus disease 2019 (COVID-19), is strongly associated with various coagulopathies that may
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result in thrombosis, thrombocytopenia, or bleeding in the later stages of the disease [1–14]. It is also
recognized that vascular changes and thrombotic microangiopathy, diffuse intravascular coagulation,
and large-vessel thrombosis are major reasons for a poor prognosis [15]. These comorbidities are
linked to multisystem organ failure, as well as pulmonary vascular endothelialitis [15]. The presence of
endotheliopathy, in particular, is likely to be associated with critical illness and death [16]. In addition,
in COVID-19, peripheral lung ground-glass opacities are an accompaniment in mild, moderate,
and severe diseases, as visible on computed tomographic (CT) images. Peripheral lung ground-glass
opacities in COVID-19 also meet the Berlin criteria for acute respiratory distress syndrome (ARDS) [15].
In a recent study by Pretorius and colleagues, microclots were also present in platelet-poor plasma
(to which thrombin was not added) of COVID-19 patients, where they form “spontaneously” [17].
Fluorescent microscopy analysis, with the addition of thioflavin T (ThT) (an amyloid protein marker),
confirmed that these microclots were in fact amyloid in nature [17]. Previously, we have found that
amyloid fibrin(ogen) is a feature of a variety of inflammatory diseases [18–23].
Recently, we discussed the apparent paradox in COVID-19 where both clotting and bleeding
can be observed as part of the pathology [14] and proposed that the resolution of the paradox is that
these clotting and bleeding phases are separated in time. The later bleeding propensity is mediated
by the earlier clotting-induced depletion of both fibrinogen and of von Willebrand factor (VWF).
Additionally, central to COVID-19 pathology is the dysregulation of P-selectin [24]. P-selectin is an
inflammatory coagulation biomarker involved in clotting, and it is known to modulate interactions
between blood cells and endothelial cells [25]. This biomarker (also known as CD62P) can either be
inside the platelets or endothelial cells, on platelet membranes, or in its soluble form (sP-selectin)
as a circulating plasma biomarker. P-selectin is constitutively present in alpha (α)-granules inside
platelets, also in Weibel-Palade bodies inside endothelial cells, or as a platelet membrane receptor after
the release from the platelet granules [25–27]. As membrane receptor, P-selectin acts as an adhesion
receptor to support leukocyte rolling and emigration at sites of inflammation [27]. Soluble P-selectin is
alternatively spliced, lacks the transmembrane domain, and plays an important role in modulating
interactions between blood cells and endothelial cells [25]. Thus, P-selectin may play a crucial role
in COVID-19 endotheliopathy, as well as platelet hyperactivation [16]. In COVID-10, P-selectin may
significantly contribute to the adhesion of both pathological and possibly also healthy erythrocytes to
damaged endothelia, as well as to adjacent erythrocytes and, also, to hyperactivated platelets. It is
known that P-selectin may mediate such an interaction in sickle cell disease.
Recently, Manne and coworkers found distinct changes in the gene expression profiles of circulating
platelets of COVID-19 patients [28]. They also found that platelets from COVID-19 patients aggregated
faster and showed increased spreading on both fibrinogen and collagen. In addition, the authors
suggested that an increase in platelet activation and aggregation could partially be attributed to increased
mitogen-activated protein kinase (MAPK) pathway activation and thromboxane generation [28].
Strongly associated with the COVID-19 coagulopathies is the presence of hyperferritinemia. Iron and
serum ferritin (a marker of oxidative stress) [29,30] in circulation can act as a marker of damaged
cells [31]. Excess circulating iron has long been known to cause blood to clot into an anomalous
form [30], later shown to be amyloid in nature [18–23,32]. Both platelets and erythrocytes also show
pathology in the presence of increased iron and serum ferritin [33,34]. Hyperferritinemia is also known
to accompany ultrastructural changes in both platelets and erythrocytes [33–38].
P-selectin, serum ferritin, and pathological changes in platelets and erythrocytes may be central to
the development of thrombotic pathophysiology and contribute to the decrease in oxygen saturation
levels commonly seen during COVID-19. Here, we propose that there is a causality between increased
concentrations of serum ferritin and P-selectin, platelet hyperactivation, and their interactions with
erythrocytes. In our recent review [14], we conclude that structural pathologies found in platelets in
particular, together with spontaneously formed microclots, may be central to vascular changes and
thrombotic microangiopathy, diffuse intravascular coagulation, and large-vessel thrombosis, as well as
ground-glass opacities in the lungs. Consequently, this clinical snapshot of COVID-19 strongly suggest
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that it is also a true vascular disease and treating it as such should form an essential part of a clinical
treatment regime.
2. Results
2.1. Blood Proteins Results
Control and COVID-19 patient laboratory results are shown in Table 1. Newly diagnosed COVID-19
patient blood samples were collected, and the blood analysis reported here was done on treatment-naïve
patients. The parameters were all done on admission (thus, symptomatic patients at different grades of
severity) and at several points during admission. In our experience, hypercoagulability (as shown
with thromboelastography (TEG®) and PFA200) could certainly predict the patients with the highest
risk of developing the severe disease. Of the 37 patients, 15 were classified as having the mild disease
and 22 as moderate-to-severe symptoms (based on CT scans); the latter group of patients were in the
ICU. Please see raw data link for the spreadsheet of the patient data.
Table 1. Sample demographics and biomarker levels (bold indicates significance).
Demographics
p-value (data normally distributed; unpaired t-test) 0.6
Mean age of healthy individuals (n = 13) 55.6 (±10.7)
Mean age of COVID-19 (n = 37) 53.1 (±14.7)
Serum Ferritin (µg·mL−1) (COVID-19: n = 33; controls: n = 13)
p-value (Mann-Whitney U test, unpaired
nonparametric data expressed as median) (Q1–Q3) 0.0009 (***)
Median of healthy individuals 113.5 (55.8–149.3)
Median of COVID-19 patients 306.6 (162.0–699.0)
CRP (µg·mL−1) (COVID-19: n = 37; controls: n = 13)
p-value (Mann-Whitney U test, unpaired
nonparametric data expressed as median) (Q1–Q3) <0.0001 (***)
Median of healthy individuals 0.8 (0.3–2.1)
Median of COVID-19 patients 44.1 (13.2–108.0)
Soluble P-selectin (ng·mL−1) (COVID-19: n = 30; controls: n = 10)
Our P-selectin (ng·mL−1) analysis Goshua et al., 2020 analysis (ng·mL−1)
p-value 0.0009 (***) p-value 0.001
Median of healthy
individuals (n = 10) 26.7 (23.9–27.2)
Median of healthy
individuals (n = 13) 9.5 (8.5–11.3)
Median of COVID-19
patients (n = 30) 17.36 (14.3–22.3)
Median of ICU COVID-19
patients (n = 48) 15.9 (4.8)
Median of non-ICU
COVID-19 patients (n = 20) 11.2 (3.1)
Our ELISA kit average
ranges for control data
15–55 (Citrate and
EDTA plasma)
Their ELISA kit insert
average for control data
25.8 (citrate plasma) and
18.3 to 57.4
(EDTA plasma)
Platelet-poor plasma viscosity (mPa·second)
p-value (data normally distributed; unpaired t-test)
(control: n = 10; COVID-19: n = 7) 0.007 (**)
Mean viscosity of healthy individuals 2.0 (±0.2)
Mean viscosity of COVID-19 samples 2.8 (±0.8)
Thromboelastography® of platelet-poor plasma (PPP)
Parameter Plasma from healthysamples (n = 10)
Plasma from COVID-19
samples (n = 7) p-value
R 16.41 (±6.1) 12.9 (±5.2) 0.1
α angle 52.4 (34.4–61.3) 46.0 (33.9–63.3) 0.7
MA 32.1 (24.5–36.0) 48.2 (35.0–53.8) 0.04 (*)
MRTG 4.7 (±3.0) 7.5 (±3) 0.04 (*)
TMRTG 17.6 (13.1–23.6) 13.2 (11.3–18.4) 0.4
TTG 237 (162.6–415.6) 577.7 (422.0–642.3) 0.009 (**)
Statistical significance was established at p < 0.05. (* = p < 0.05, ** = p < 0.01, and *** = p < 0.001). Data is represented
as either mean ± standard deviation or median (Q1–Q3). CRP: C-reactive protein, COVID-19: coronavirus disease
2019, R: reaction time, α: alpha, MA: maximal amplitude, MRTG: maximum rate of thrombus generation, TMRTG:
time to maximum rate of thrombus generation, and TTG: total thrombus generation.
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We age-matched COVID-19 (mean age: 53.1 y) and healthy individuals (mean age: 55.6 y) (p = 0.6;
data normally distributed and analysis done using unpaired t-test). Oxygen saturation was low in
COVID-19 patients 94.6% (91–96%). Oxygen saturation of healthy individuals are usually between
97% and 100%. COVID-19 patients also have significantly raised C-reactive protein (CRP) and serum
ferritin levels (see Table 1).
2.2. Fluorescent Microscopy Results
Figure 1A–F show the representative fluorescent microscope micrographs of healthy and
COVID-19 samples stained with PAC-1 (green fluorescence—activated GPIIb/IIIa) and CD62P-PE
(purple fluorescence—platelet surface P-selectin). Control platelets are typically small, round cellular
entities with only a few pseudopodia extending from their surfaces. Platelets from COVID-19 patients
showed extensive platelet hyperactivation; in some instances, severe aggregation and spreading were
seen (Figure 1B–F).
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Figure 1. (A–F) Representative fluorescent micrographs of whole-blood samples stained with PAC-1
(green fluorescence) and CD62P-PE (purple fluorescence). The last column represents an overlay of
the two micrographs. (A) Representative healthy (control) platelets. (B–F) Representative fluorescent
micrographs from coronavirus disease 2019 (COVID-19) patients.
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2.3. Scanning Electron Microscopy Results
Figure 2A,B shows scanning electron micrographs from healthy erythrocytes (Figure 2A) and
platelets (Figure 2B), while Figure 3A–H show platelets from COVID-19 patients. Results from SEM
analysis support the fluorescence microscopy results seen in Figure 1, where severe platelet pathologies
(spreading and clumping) were visualized with PAC-1 and CD62P-PE. Extensive hyperactivation and
clumping were noted in the platelet ultrastructure (Figure 3A,B), with platelet membrane damage,
where the membranes are fragmented and granular, were also seen (Figure 3C–H: yellow arrows).
We propose that the significant platelet pathophysiology seen in both Figures 1 and 3 suggest that the
sP-selectin, which we would expect to be in circulation, may either be bound to receptors on platelets
(and other blood cells, including possibly also endothelial cells) or P-selectin may still be present on the
platelet membrane where it acts as a binding receptor, facilitating binding between adjacent platelets,
red blood cells (RBCs), and also, endothelial cells. This explains the significantly lower sP-selectin
values that we report here in Table 1 and confirms the results from Goshua and coworkers in 2020 [16].
Figures 4 and 5 show the erythrocyte and platelet interactions in COVID-19-positive whole-blood
(WB) samples. Figure 5A,C,E shows low magnification micrographs of the platelet-erythrocyte
interactions, while the corresponding micrographs in the right column (Figure 5B,D,F) are higher
magnification micrographs of the same erythrocyte and platelet to show the ultrastructure of the
interactions. In control WB smears, healthy erythrocytes have a typical discoid shape, and platelets are
small, round cellular elements that will show slight pseudopodia formations due to contact activation
in the glass coverslip on which the WB samples are placed, as seen in Figure 2A,B. In WB samples
from COVID-19 patients, minimal erythrocytes show slight eryptotic changes, where the cells do not
have the typical discoid shape (Figure 4A,B,D). Hyperactivated platelet and erythrocyte interactions
frequently occur in WB smears, where both the erythrocyte and the platelet membranes are fused with
each other. Such fusions between membranes can be facilitated by P-selectin when present on the
platelet membrane. When on the platelet membrane, P-selectin is known to act as adhesion receptor,
where it promotes platelet-platelet, platelet-endothelial cells, or platelet-erythrocyte adhesions [14,39].
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ultrastructure (B) seen in healthy individuals. Yellow arrow points to a platelet in a whole-blood smear.
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2.4. Viscoelasticity and Viscometry Results
Viscoelasticity and viscometry were also done on PPP samples to determine if the fibrin(ogen)
deposits noted in the scanning electron micrographs may indeed affect the clotting parameters,
as well as the viscosity of the blood. These results are shown in Table 1. Plasma from COVID-19
patients were significantly more viscous than that of healthy individuals (p = 0.02) when measured
with the viscometer. Similarly, the TEG® results indicated that the plasma from COVID-19 patients
were significantly hypercoagulable compared to healthy plasma. Three TEG® parameters that
were significantly increased confirmed the clotting pathology. The parameters include the maximal
amplitude (MA), which reflects the ultimate strength of the fibrin clot, as well as the overall stability of
the clot. The larger the MA, the more hypercoagulable/stronger the clot. The total thrombus generation
(TTG) parameter, indicative of clot strength, and the amount of total resistance (to movements of the
cup and pin) generated during clot formation were also significantly increased. In addition, the time
parameter, the maximum rate of thrombus generation (MRTG), was also significantly decreased in
COVID-19 plasma. MRTG is an indication of the maximum rate of the clot growth. These parameters
point to a hypercoagulable clot pathology in COVID-19 patients and confirm our previous results,
as well as underscore the ultrastructural changes noted in WB smears [17].
Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 8 of 14 
 
Viscoelasticity and viscometry were also done on PPP samples to determine if the fibrin(ogen) 
deposits noted in the scanning electron micrographs may indeed affect the clotting parameters, as 
well as the viscosity of the blood. These results are shown in Table 1. Plasma from COVID-19 patients 
were significantly more viscous than that of healthy individuals (p = 0.02) when measured with the 
viscometer. Similarly, the TEG® results indicated that the plasma from COVID-19 patients were 
significantly hypercoagulable compared to healthy plasma. Three TEG® parameters that were 
significantly increased confirmed the clotting pathology. The parameters include the maximal 
amplitude (MA), which reflects the ultimate strength of the fibrin clot, as ell as the overall stability 
of the clot. The larger the MA, the more hypercoagulable/stronger the clot. The t tal thrombus 
gene tion (TTG) p rameter, indicative of clot strength, and he amount of to al resistance (t  
movements of the cup and pin) generated during clot formation were also significantly increased. In 
addition, the time parameter, the maximum rate of thrombus generation (MRTG), was also 
significantly decreased in COVID-19 plasma. MRTG is an indication of the maximum rate of the clot 
growth. These parameters point to a hypercoagulable clot pathology in COVID-19 patients and 
confirm our previous results, as well as underscore the ultrastructural changes noted in WB smears 
[17]. 
 
Figure 6. (A–D) Representative scanning electron micrographs of COVID-19-positive samples with 
spontaneous fiber-like clotlet formations in close proximity to erythrocytes in whole-blood smears, as 
well as occasional granular deposits (E–H) on the erythrocytes. 
Figure 6. (A–D) Representative scanning electron micrographs of COVID-19-positive samples with
spontaneous fiber-like clotlet formations in close proximity to erythrocytes in whole-blood smears, as
well as occasional granular deposits (E–H) on the erythrocytes.
Int. J. Mol. Sci. 2020, 21, 8234 9 of 14
3. Discussion
In this current COVID-19 pandemic, the race for answers of how this virus interacts with the
body is one of the crucial research questions that need to be answered to obtain a clearer image
of how the virus works, as well as make it possible to find treatment regimens that can assist in a
COVID-19 patient’s survival. In our current research, it comes as no surprise that serum ferritin
levels are increased in COVID-19 blood samples, as it is known as a marker of damaged cells [31].
Its presence in the circulation may cause pathology to platelet erythrocytes, as well as the plasma
protein fibrinogen [18–23,32–38]. Iron can also leak into the circulation due to cellular damage to not
only erythrocytes but, also, endothelial and other cells. Both iron and serum ferritin may result in the
Fenton reaction that may drive oxidative stress in circulation [29,31,40]. Central to COVID-19 pathology
is a decreased oxygen saturation, and this was also noted in our COVID-19 sample, and oxidative stress
may be a fundamental driver of this clinical parameter. The increase in the CRP levels further confirms
the increased inflammatory conditions (hypercoagulability and activated platelets) in COVID-19
patients, as CRP is an acute marker of inflammation but, also, plays a role in the acute-phase immune
response in the body [41].
An interesting observation was that the COVID-19 individuals have a decreased P-selectin
concentration compared to our control sample (see Table 1). Our COVID-19 concentrations are broadly
comparable to those found by [16] (our median concentration was 17.4 ng·mL−1 vs. results from two
COVID-19 patient groups of the Goshua et al. paper, which were 15.9 ng·mL−1 and 11.2 ng·mL−1,
respectively). However, our sP-selectin concentrations in controls were much higher: 26.7 ng·mL−1
and, rather, compared well to that of the results of the ELISA assay kit insert (Goshua et al. paper)
that reported a control mean of detectable concentrations (ng·mL−1) of 25.8 ng·mL−1 for citrate plasma
analysis [42]. Our ELISA assay kit control ranges are considered to be 15 ng·mL−1 to 55 ng·mL−1 (personal
communication FineTest Technical Department). Our sample of COVID-19 patients showed extensive
platelet pathophysiology, as seen with fluorescent microscopy, as well as SEM analysis. P-selectin may
be present in various parts of the blood fraction, either inside platelets and endothelial cells, as a binding
receptor on platelet membranes, or as sP-selectin in circulation, where it may act as a biomarker that
can activate receptors on either platelets or other cells (including the endothelial cells). We report
extensive P-selectin signals on platelets from COVID-19 patients and, therefore, suggest that one reason
might be because P-selectin is still present as an adhesion receptor attached to the platelet membrane,
where it assists in platelet aggregation. Another reason may be that P-selectin was shed as sP-selectin
but that it is now bound to receptors on activated platelets (and other cells where it has receptors, e.g.,
endothelial cells). This will result in a decrease of sP-selectin but explains the significant signal present
on large platelet aggregates and, also, on microparticles, which are visible both with the SEM, as well as
the fluorescent microscope. Manne and coworkers suggested that COVID-19 is associated with platelet
hyper-reactivity, which may contribute to COVID-19 pathophysiology [28], and our results support
their findings. SEM also revealed a noteworthy presence of spontaneous fiber-like clotlet deposits
in the WB smears, with the occasional granular deposits on the erythrocyte membranes. Previously,
we reported that platelet-poor plasma of COVID-19 patients had a significantly increased amount of
amyloid clotlets [17]. Our TEG® and viscometry results also showed that our COVID-19 samples were
significantly hypercoagulable and more viscous than that of healthy PPP. The various plasma proteins
and their effects on blood clotting and viscosity, together with the presence of the noteworthy activated
and aggregated platelets—that is, the cause of platelets and erythrocytes to form aggregates in WB may
be the direct cause of vascular pathologies noted in the lungs of COVID-19 patients [14,17].
4. Materials and Methods
4.1. Ethical Statement
Prior to sample collection, consent was obtained from all participants. The Health Research
Ethics Committee (HREC) of Stellenbosch University approved the study (reference number: 9521).
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This laboratory study was carried out in strict adherence to the International Declaration of Helsinki,
South African Guidelines for Good Clinical Practice and the South African Medical Research Council
(SAMRC), Ethical Guidelines for Research.
4.2. Patient Samples
4.2.1. Covid-19 Patients
Thirty-seven COVID-19-positive samples (18 males and 19 females) were obtained, and blood
samples collected before treatment was embarked upon. Sample analyses that were included in this
paper were on treatment-naïve COVID-19 patients. Whole-blood (WB) samples were collected from
newly diagnosed patients before treatment, and platelet-poor plasma (PPP) were also prepared by
centrifuging samples at 3000× g for 15 min. Platelet-poor plasma was stored at −80 ◦C until necessary
for analysis (ELISA, thromboelastography, and viscometry); then, the PPP was allowed to thaw until
it reached room temperature. The WB samples were prepared on the same day for fluorescent and
scanning electron microscopy analyses.
4.2.2. Healthy Samples
Our healthy PPP samples were 13 age-matched controls (5 males and 8 females) previously
collected and stored in our plasma repository. They were nonsmokers, with C-reactive protein (CRP)
levels within normal ranges, and none were on any anti-inflammatory medication.
4.3. Fluorescence Microscopy
Two fluorescent antibodies, CD62P (platelet surface P-selectin) and PAC-1 (activated GP IIb/IIIa),
were added to WB to study platelet activation [43]. CD62P is found on the membrane of platelets and
the move to the surface of the platelet membrane. This translocation happens after platelet P-selectin
is released from the cellular granules during platelet activation. The antibody PAC-1 detects the
neoepitope of active GPIIb/IIIa. PAC-1 antibody binding is correlated with platelet activation.
We added 4 µL of PAC-1 (FITC-conjugated) (340507, BD Biosciences, San Jose, CA, USA) and 4 µL
CD62P (PE-conjugated) (IM1759U, Beckman Coulter, Brea, CA, USA) to 20-µL WB and incubated the
samples for 30 min (protected from light) at room temperature. A 10-µL drop of blood was then placed
on a microscope slide, and a coverslip was then placed on the drop of blood. Following preparation,
the samples were viewed using a Zeiss Axio Observer 7 fluorescent microscope with a Plan-Apochromat
63x/1.4 Oil DIC M27 objective (Carl Zeiss Microscopy, Munich, Germany). For the PAC-1 marker,
the excitation wavelength was set at 450 to 488 nm and the emission at 499 to 529 nm, while the
excitation for the CD62P was 540 to 570 nm and the emission 577 to 607 nm. Unstained samples were
also prepared with COVID-19 WB to assess any interference from autofluorescence.
4.4. Scanning Electron Microscopy
Whole-blood samples were also prepared for scanning electron microscopy (SEM) analysis to
assess ultrastructural changes of the erythrocytes and platelets. Ten-microliter WB was placed on
a 10-mm round glass coverslip and exposed to 0.075-M sodium potassium phosphate buffer (PBS).
Standard SEM preparation steps were followed, including fixing in 4% formaldehyde and a secondary
fixation of the sample in 1% osmium tetroxide (OsO4). Dehydration steps in an increasing series of
ethanol was followed, with the final step, hexamethyldisilazane (HMDS). The samples were coated
with carbon and viewed with a Zeiss MERLIN field emission-SEM with the InLens detector using 1 kV
(Carl Zeiss Microscopy, Munich, Germany).
4.5. P-Selectin ELISA, CRP, and Serum Ferritin
We analyzed soluble P-selectin concentrations in PPP samples of 10 control and 30 COVID-19
samples using the EH3818 Human sSELP (soluble P-Selectin) ELISA Kit (FineTest, Wuhan, China).
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Serum ferritin and CRP concentrations were measured at the PathCare pathology laboratory in
Stellenbosch, Western Cape, South Africa. CRP was measured on the AU480 Beckman Coulter machine
(Brea, CA, USA) and serum ferritin on the DXI Beckman Coulter machine (Brea, CA, USA). CRP data
was cross-checked using a VPLEX multiplex assay (Vascular Injury Panel (V-plex) 2 (human) kits,
catalogue number: K15198D, Meso Scale Discover (MSD), Rockville, MD, USA).
4.6. Thromboelastography (TEG®)
TEG® was performed to assess the clot kinetics and viscoelastic properties of PPP samples from
COVID-19 patients (n = 7) and healthy control subjects (n = 10). Samples were prepared by the addition
of 20-µL 0.2-M calcium chloride (CaCl2) (7003, Haemonetics®, Niles, IL, USA) to a disposable TEG®
cup (HAEM 6211, Haemonetics®, Niles, IL, USA), followed by the addition of 340 µL of citrated PPP.
CaCl2 was added to reverse the anticoagulant action of sodium citrate (recalcification of blood) and,
consequently, activate the coagulation cascade. Samples were loaded in the measuring channels of
the TEG® 5000 Hemostasis Analyzer System (07-033, Haemonetics®, Niles, IL, USA), and analyses
were performed at 37 ◦C. TEG® parameters measured included the reaction time (R, minutes),
alpha-angle (α, degrees), maximum amplitude (MA, mm), maximum rate of thrombus generation
(MRTG, dynes/cm2/s), time to maximum rate of thrombus generation (TMRTG, minutes), and total
thrombus generation (TTG, dynes/cm2) (see Table 2 for the various parameters of this method).
Table 2. Definitions of the various thromboelastography (TEG®) parameters, adapted from [23].
TEG® Parameters Explanation
R value: reaction time
measured in minutes
Time of latency from start of test to initial fibrin formation (amplitude of
2 mm); i.e., initiation time.
Alpha-angle (α, degrees) The rate of fibrin crosslinking indicated by degrees.
MA: maximal amplitude
measured in mm
Maximum clot size: it reflects the ultimate strength of the fibrin clot, i.e.,
overall stability of the clot. The larger the MA, the more hypercoagulable
the clot.
Maximum rate of thrombus
generation (MRTG) measured
in Dyn·cm−2·s−1
The maximum velocity of clot growth observed or maximum rate of
thrombus generation using G, where G is the elastic modulus strength of the
thrombus in dynes per cm−2.
Time to maximum rate of
thrombus generation (TMRTG)
measured in minutes
The time interval observed before the maximum speed of the clot growth.
Total thrombus generation
(TTG) measured in Dyn·cm−2
The clot strength: the amount of total resistance (to movement of the cup
and pin) generated during clot formation. This is the total area under the
velocity curve during clot growth, representing the amount of clot strength
generated during clot growth.
4.7. Viscometry
Plasma viscosity was measured with the RheoSense microVISC™ (RheoSense Inc., San Ramon,
CA, USA) viscometer, which uses viscometer/rheometer On-a-Chip (VROC®) microfluidic sensor
technology. Prior to analysis, stored PPP aliquots from SARS-CoV-2 patients (n = 7) and healthy
control subjects (n = 10) were thawed form −80 ◦C to room temperature (~19 ◦C). Between each
measurement, the microviscometer was cleaned with 1% Scienceware® Aquet® liquid detergent
solution (Z273260, Sigma-Aldrich, St. Louis, Missouri, USA) in order to maintain stable viscosity
measurements. Plasma viscosity was calculated according to Newton’s law of viscosity:
µ = τ/(γapp) (1)
where µ = viscosity, τ = shear stress, and γapp = apparent shear rate.
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4.8. Statistics
Statistical analysis was done using GraphPad Prism 8 (version 8.4.3, San Diego, CA, USA).
The Shapiro-Wilks normality test was done on all data. Parametric datasets were analyzed using
an unpaired t-test, and the data expressed as mean ± standard deviation. Nonparametric data sets
were analyzed using the Mann-Whitney U test, and the unpaired nonparametric data (all two-tailed)
were expressed as medians (Q1–Q3). Raw data of the results can be viewed at the following link:
https://1drv.ms/u/s!AgoCOmY3bkKHisVGQ63lwdCsZBlimA?e=4lWhlw.
5. Conclusions
Although progressive respiratory failure is seen as a primary cause of death in COVID-19
patients, respiratory failure may be significantly linked to microclots in the circulation and, specifically,
in the lungs. Relevant molecular players, particularly P-selectin, may be important early markers
of severe vascular disease risk, particularly if soluble P-selectin levels are decreased, as we noted in
our results. In addition, the observation of structural changes in the plasma, where microclots and
large platelet aggregates are visible, may also lead to important point-of-care analyses that may assist
clinicians to plan clinical interventions relating to anticoagulation therapies. Although a high-end
fluorescence microscope was used in this research, less expensive fluorescence microscopes may be
used as a quick-point point-of-care method. Consequently, fluorescence microscopy, together with
thromboelastrography and viscometry, might provide clinicians with critical information in real time
about the functioning of platelets and plasma-clotting proteins. COVID-19 is, therefore, a true vascular
disease, and treating it as such should form an essential part of a clinical therapeutic regime.
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Abbreviations
COVID-19 Coronavirus disease 2019
sP-selectin Soluble P-selectin
SEM Scanning electron microscope
TEG® Thromboelastography
R value reaction time measured in minutes
Alpha-angle (α, degrees)
MA Maximal amplitude measured in mm
MRTG Maximum rate of thrombus generation, measured in Dyn·cm−2·s−1
TMRTG Time to maximum rate of thrombus, measured in minutes generation
TTG Total thrombus generation, measured in Dyn·cm−2
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